Healthcare Business

Health Care Stocks Cheapest in 30 Years: 5 With Big Dividends to Buy Now

Amgen

This biotech giant remains a top stock for investors to buy and a safer way to play the massive potential growth in biosimilars. Amgen Inc. (NASDAQ: AMGN) discovers, develops, manufactures and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.

The company’s products include the following:

  • Enbrel to treat plaque psoriasis, rheumatoid arthritis and psoriatic arthritis
  • Neulasta reduces the chance of infection due a low white blood cell count in patients cancer
  • Prolia to treat postmenopausal women with osteoporosis
  • Xgeva for skeletal-related events prevention
  • Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behcet’s disease
  • Aranesp to treat a lower-than-normal number of red blood cells and anemia
  • Kyprolis to treat patients with relapsed or refractory multiple myeloma
  • Repatha, which reduces the risks of myocardial infarction, stroke and coronary revascularization

Amgen also markets Nplate, Vectibix, Mvasi, Parsabiv, Epogen, Kanjinti, Blincyto, Aimovig, Evenity, Amgevitatm, Sensipar/Mimpara, Neupogen, Imlygic, Corlanor and Avsola. The company’s five key marketed products are among the top-selling pharmaceutical products in the world, with the company having expected collective revenues of more than $25 billion in 2021.

Amgen stock investors receive a 3.42% dividend. BMO Capital Markets has a Wall Street high $301 price target. The consensus target is $244.81, and the final trade for Wednesday came in at $205.82.

Bristol-Myers Squibb

This top company remains a solid pharmaceutical stock to own long-term and the stock is offering an outstanding entry point after a tumble. Bristol Myers Squibb Co. (NYSE: BMY) discovers, develops, licenses, manufactures and markets pharmaceutical products worldwide in the hematology, oncology, cardiovascular and immunology therapeutic classes.

Its products include the following:

  • Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma
  • Opdivo for anti-cancer indications
  • Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders
  • Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
  • Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia
  • Yervoy for the treatment of patients with unresectable or metastatic melanoma
  • Abraxane, a protein-bound chemotherapy product
  • Reblozyl for the treatment of anemia in adult patients with beta thalassemia

The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies. It has collaboration agreements with Pfizer, Otsuka Pharmaceutical, Ono Pharmaceutical, Nektar Therapeutics; AVEO Pharmaceuticals, Huyabio, DarwinHealth and Bolt Biotherapeutics.

Shareholders receive a 3.30% dividend. BofA Securities has a $78 price target on Bristol-Myers Squibb stock. The consensus target is $73.18, and shares closed most recently at $59.44.

Sponsored: Find a Qualified Financial Advisor

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.